Upregulation of immune checkpoint ligands PD-L1 and PD-L2 is often seen in melanoma and other cancers in response to robust inflammatory signals as a homeostatic mechanism adopted by cancer cells to shield themselves from immune attack. The gene discussed is PDCD1LG2; the disease is melanoma.